MacroGenics, Inc. (NASDAQ:MGNX) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, July 31st.
A number of other research analysts have also recently commented on the company. Morgan Stanley dropped their price target on MacroGenics from $24.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, May 8th. Zacks Investment Research raised MacroGenics from a “sell” rating to a “hold” rating and set a $19.00 price objective for the company in a research report on Tuesday, July 18th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $32.30.
MacroGenics (NASDAQ MGNX) traded up 2.59% on Monday, hitting $16.24. 122,710 shares of the stock were exchanged. MacroGenics has a 52 week low of $14.36 and a 52 week high of $33.30. The company’s 50-day moving average is $17.42 and its 200-day moving average is $18.74. The company’s market cap is $597.60 million.
MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.09. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The firm’s revenue was down 97.9% on a year-over-year basis. On average, analysts predict that MacroGenics will post ($4.36) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “MacroGenics, Inc. (MGNX) Downgraded by BidaskClub to Sell” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/08/11/macrogenics-inc-mgnx-downgraded-by-bidaskclub-to-sell-updated.html.
In related news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the sale, the senior vice president now owns 35,000 shares of the company’s stock, valued at approximately $700,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Airain ltd acquired a new stake in MacroGenics during the first quarter valued at about $470,000. Wells Fargo & Company MN increased its position in shares of MacroGenics by 100.8% in the first quarter. Wells Fargo & Company MN now owns 48,200 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 24,198 shares during the period. American International Group Inc. increased its position in shares of MacroGenics by 7.1% in the first quarter. American International Group Inc. now owns 19,632 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 1,300 shares during the period. Marshall Wace North America L.P. purchased a new position in shares of MacroGenics during the first quarter valued at approximately $4,514,000. Finally, BB Biotech AG increased its position in shares of MacroGenics by 17.7% in the first quarter. BB Biotech AG now owns 2,260,000 shares of the biopharmaceutical company’s stock valued at $42,036,000 after buying an additional 340,000 shares during the period. 82.34% of the stock is currently owned by hedge funds and other institutional investors.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
What are top analysts saying about MacroGenics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MacroGenics Inc. and related companies.